Histology is a dominant factor in determining outcome in patients with recurrent glioma enrolled onto phase II trials. Future trials should be designed with separate histology strata.

Me gusta

Guardar

Me gusta

Guardar

Cite This Study

Wong et al. (Sun,) studied this question.

synapsesocial.com/papers/69dc53b445b398e6439f579a https://doi.org/https://doi.org/10.1200/jco.1999.17.8.2572

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Growth inhibitory effect of recombinant ? and ? interferon on human glioma cells1987 · 29 citations
2AGE-RELATED CHEMOSENSITIVITY OF STEM CELLS FROM HUMAN MALIGNANT BRAIN TUMOURS1982 · 78 citations
3Resection and Reoperation in Neuro-oncology: Rationale and Approach1985 · 34 citations
4Age influences chemotherapy response in astrocytomas1995 · 73 citations
5Primary Tumors of the Brain and Spinal Cord1997 · 5 citations

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Growth inhibitory effect of recombinant ? and ? interferon on human glioma cells1987 · 29 citations
2AGE-RELATED CHEMOSENSITIVITY OF STEM CELLS FROM HUMAN MALIGNANT BRAIN TUMOURS1982 · 78 citations
3Resection and Reoperation in Neuro-oncology: Rationale and Approach1985 · 34 citations
4Age influences chemotherapy response in astrocytomas1995 · 73 citations
5Primary Tumors of the Brain and Spinal Cord1997 · 5 citations